Thinly traded micro cap DermTech (NASDAQ:DMTK) is up 13% premarket on light volume in reaction to its announcement that Medicare has finalized reimbursement for its Pigmented Lesion Assay (PLA) as an aid to rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more clinical or historical characteristics suggestive of melanoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.